Home » Acorda Obtains FDA Nod for Oral Drug to Improve Walking in MS Patients
Acorda Obtains FDA Nod for Oral Drug to Improve Walking in MS Patients
Acorda Therapeutics received approval to market Ampyra in the
U.S. to improve walking in patients with multiple sclerosis.
GEN
GEN
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May